Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes

Natalia Battista, Monica Bari, Alessia Tarditi, Caterina Mariotti, Anne Catherine Bachoud-Lévi, Chiara Zuccato, Alessandro Finazzi-Agrò, Silvia Genitrini, Marc Peschanski, Stefano Di Donato, Elena Cattaneo, Mauro Maccarrone

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

The search for peripheral markers of neurodegenerative diseases aims at identifying molecules that could help in monitoring the effects of future therapeutics in easily accessible cells. Here we focused on the involvement of the endocannabinoid system in Huntington's disease (HD). We assayed peripheral lymphocytes from HD patients and healthy controls, and found that the activity of the fatty acid amide hydrolase (FAAH), the enzyme that degrades the endocannabinoid anandamide (AEA), was dramatically decreased (down to less than 10%) in HD compared to healthy subjects. Concomitantly, the endogenous levels of AEA were ∼ 6-fold higher in HD versus healthy lymphocytes, while the other elements of the endocannabinoid system were not affected by HD. Low FAAH activity in HD lymphocytes was not due to down-regulation of protein expression, but rather to blockage of enzyme activity by a cytosolic and irreversible inhibitor. Finally, pre-HD patients showed defective FAAH activity, as did the brain of HD patients compared with healthy controls. Taken together, our data indicate that FAAH activity in lymphocytes mirrors some of the metabolic changes which take place in the brain, it is a measurable non-genetic peripheral marker that segregates with the HD mutation, and it might serve as a target to test chemicals active on the widespread toxic effects of the mutant protein.

Original languageEnglish
Pages (from-to)108-116
Number of pages9
JournalNeurobiology of Disease
Volume27
Issue number1
DOIs
Publication statusPublished - Jul 2007

Fingerprint

Huntington Disease
Lymphocytes
Mutation
Endocannabinoids
fatty-acid amide hydrolase
Poisons
Brain Diseases
Therapeutic Uses
Mutant Proteins
Enzymes
Neurodegenerative Diseases
Healthy Volunteers
Down-Regulation
Brain

Keywords

  • Endocannabinoid
  • Enzyme inhibition
  • FAAH
  • Huntington's disease
  • Lymphocyte

ASJC Scopus subject areas

  • Neurology

Cite this

Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes. / Battista, Natalia; Bari, Monica; Tarditi, Alessia; Mariotti, Caterina; Bachoud-Lévi, Anne Catherine; Zuccato, Chiara; Finazzi-Agrò, Alessandro; Genitrini, Silvia; Peschanski, Marc; Di Donato, Stefano; Cattaneo, Elena; Maccarrone, Mauro.

In: Neurobiology of Disease, Vol. 27, No. 1, 07.2007, p. 108-116.

Research output: Contribution to journalArticle

Battista, N, Bari, M, Tarditi, A, Mariotti, C, Bachoud-Lévi, AC, Zuccato, C, Finazzi-Agrò, A, Genitrini, S, Peschanski, M, Di Donato, S, Cattaneo, E & Maccarrone, M 2007, 'Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes', Neurobiology of Disease, vol. 27, no. 1, pp. 108-116. https://doi.org/10.1016/j.nbd.2007.04.012
Battista, Natalia ; Bari, Monica ; Tarditi, Alessia ; Mariotti, Caterina ; Bachoud-Lévi, Anne Catherine ; Zuccato, Chiara ; Finazzi-Agrò, Alessandro ; Genitrini, Silvia ; Peschanski, Marc ; Di Donato, Stefano ; Cattaneo, Elena ; Maccarrone, Mauro. / Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes. In: Neurobiology of Disease. 2007 ; Vol. 27, No. 1. pp. 108-116.
@article{8d041b0e462742a5a44c7ce0c11f0462,
title = "Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes",
abstract = "The search for peripheral markers of neurodegenerative diseases aims at identifying molecules that could help in monitoring the effects of future therapeutics in easily accessible cells. Here we focused on the involvement of the endocannabinoid system in Huntington's disease (HD). We assayed peripheral lymphocytes from HD patients and healthy controls, and found that the activity of the fatty acid amide hydrolase (FAAH), the enzyme that degrades the endocannabinoid anandamide (AEA), was dramatically decreased (down to less than 10{\%}) in HD compared to healthy subjects. Concomitantly, the endogenous levels of AEA were ∼ 6-fold higher in HD versus healthy lymphocytes, while the other elements of the endocannabinoid system were not affected by HD. Low FAAH activity in HD lymphocytes was not due to down-regulation of protein expression, but rather to blockage of enzyme activity by a cytosolic and irreversible inhibitor. Finally, pre-HD patients showed defective FAAH activity, as did the brain of HD patients compared with healthy controls. Taken together, our data indicate that FAAH activity in lymphocytes mirrors some of the metabolic changes which take place in the brain, it is a measurable non-genetic peripheral marker that segregates with the HD mutation, and it might serve as a target to test chemicals active on the widespread toxic effects of the mutant protein.",
keywords = "Endocannabinoid, Enzyme inhibition, FAAH, Huntington's disease, Lymphocyte",
author = "Natalia Battista and Monica Bari and Alessia Tarditi and Caterina Mariotti and Bachoud-L{\'e}vi, {Anne Catherine} and Chiara Zuccato and Alessandro Finazzi-Agr{\`o} and Silvia Genitrini and Marc Peschanski and {Di Donato}, Stefano and Elena Cattaneo and Mauro Maccarrone",
year = "2007",
month = "7",
doi = "10.1016/j.nbd.2007.04.012",
language = "English",
volume = "27",
pages = "108--116",
journal = "Neurobiology of Disease",
issn = "0969-9961",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes

AU - Battista, Natalia

AU - Bari, Monica

AU - Tarditi, Alessia

AU - Mariotti, Caterina

AU - Bachoud-Lévi, Anne Catherine

AU - Zuccato, Chiara

AU - Finazzi-Agrò, Alessandro

AU - Genitrini, Silvia

AU - Peschanski, Marc

AU - Di Donato, Stefano

AU - Cattaneo, Elena

AU - Maccarrone, Mauro

PY - 2007/7

Y1 - 2007/7

N2 - The search for peripheral markers of neurodegenerative diseases aims at identifying molecules that could help in monitoring the effects of future therapeutics in easily accessible cells. Here we focused on the involvement of the endocannabinoid system in Huntington's disease (HD). We assayed peripheral lymphocytes from HD patients and healthy controls, and found that the activity of the fatty acid amide hydrolase (FAAH), the enzyme that degrades the endocannabinoid anandamide (AEA), was dramatically decreased (down to less than 10%) in HD compared to healthy subjects. Concomitantly, the endogenous levels of AEA were ∼ 6-fold higher in HD versus healthy lymphocytes, while the other elements of the endocannabinoid system were not affected by HD. Low FAAH activity in HD lymphocytes was not due to down-regulation of protein expression, but rather to blockage of enzyme activity by a cytosolic and irreversible inhibitor. Finally, pre-HD patients showed defective FAAH activity, as did the brain of HD patients compared with healthy controls. Taken together, our data indicate that FAAH activity in lymphocytes mirrors some of the metabolic changes which take place in the brain, it is a measurable non-genetic peripheral marker that segregates with the HD mutation, and it might serve as a target to test chemicals active on the widespread toxic effects of the mutant protein.

AB - The search for peripheral markers of neurodegenerative diseases aims at identifying molecules that could help in monitoring the effects of future therapeutics in easily accessible cells. Here we focused on the involvement of the endocannabinoid system in Huntington's disease (HD). We assayed peripheral lymphocytes from HD patients and healthy controls, and found that the activity of the fatty acid amide hydrolase (FAAH), the enzyme that degrades the endocannabinoid anandamide (AEA), was dramatically decreased (down to less than 10%) in HD compared to healthy subjects. Concomitantly, the endogenous levels of AEA were ∼ 6-fold higher in HD versus healthy lymphocytes, while the other elements of the endocannabinoid system were not affected by HD. Low FAAH activity in HD lymphocytes was not due to down-regulation of protein expression, but rather to blockage of enzyme activity by a cytosolic and irreversible inhibitor. Finally, pre-HD patients showed defective FAAH activity, as did the brain of HD patients compared with healthy controls. Taken together, our data indicate that FAAH activity in lymphocytes mirrors some of the metabolic changes which take place in the brain, it is a measurable non-genetic peripheral marker that segregates with the HD mutation, and it might serve as a target to test chemicals active on the widespread toxic effects of the mutant protein.

KW - Endocannabinoid

KW - Enzyme inhibition

KW - FAAH

KW - Huntington's disease

KW - Lymphocyte

UR - http://www.scopus.com/inward/record.url?scp=34250361495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250361495&partnerID=8YFLogxK

U2 - 10.1016/j.nbd.2007.04.012

DO - 10.1016/j.nbd.2007.04.012

M3 - Article

VL - 27

SP - 108

EP - 116

JO - Neurobiology of Disease

JF - Neurobiology of Disease

SN - 0969-9961

IS - 1

ER -